Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial (vol 7, e214761, 2021)

被引：0
|
作者：
Feng, Jean [1 ]
Friesner, Isabel [1 ]
Hong, Julian C. [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
来源：
JAMA ONCOLOGY | 2024年 / 10卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1443 / 1443
页数：1
相关论文
共 50 条
  • [41] Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study (vol 22, pg 959, 2021)
    Gainor, Justin F.
    Curigliano, Giuseppe
    Kim, Dong-Wan
    Lee, Dae Ho
    Besse, Benjamin
    Baik, Christina S.
    Doebele, Robert C.
    Cassier, Philippe A.
    Lopes, Gilberto
    Tan, Daniel S. W.
    Garralda, Elena
    Paz-Ares, Luis G.
    Cho, Byoung Chul
    Gadgeel, Shirish M.
    Thomas, Michael
    Liu, Stephen V.
    Taylor, Matthew H.
    Mansfield, Aaron S.
    Zhu, Viola W.
    Clifford, Corinne
    Zhang, Hui
    Palmer, Michael
    Green, Jennifer
    Turner, Christopher D.
    Subbiah, Vivek
    LANCET ONCOLOGY, 2021, 22 (08): : E347 - E347
  • [42] BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab plus Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer
    Hainsworth, John D.
    Fang, Liang
    Huang, Jane E.
    Karlin, David
    Russell, Kenneth
    Faoro, Leonardo
    Azzoli, Christopher
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (01) : 109 - 114
  • [43] Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)
    Hayashi, Hidetoshi
    Yonesaka, Kimio
    Nakamura, Atsushi
    Fujimoto, Daichi
    Azuma, Koichi
    Sakata, Shinya
    Tachihara, Motoko
    Ikeda, Satoshi
    Yokoyama, Toshihide
    Hataji, Osamu
    Yano, Yukihiro
    Hirano, Katsuya
    Daga, Haruko
    Okada, Hideaki
    Chiba, Yasutaka
    Sakai, Kazuko
    Nishio, Kazuto
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    LUNG CANCER, 2022, 168 : 38 - 45
  • [44] EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability
    Michels, S.
    Nogova, L.
    Deschler-Baier, B.
    Sebastian, M.
    Schuler, M.
    Wermke, M.
    Felip, E.
    Rodriguez-Abreu, D.
    Rosell, R.
    Abdulla, D. S. Y.
    Fischer, R. N.
    Koleczko, S.
    Kron, A.
    Pinto, A.
    Riedel, R.
    Scheffler, M.
    Sueptitz, J.
    Fassunke, J.
    Merkelbach-Bruse, S.
    Hellmich, M.
    Buettner, R.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 111 - 111
  • [45] Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
    Yu, Yongfeng
    Zhou, Jianya
    Li, Xingya
    Goto, Koichi
    Min, Xuhong
    Nishino, Kazumi
    Cui, Jiuwei
    Wu, Lin
    Sakakibara, Jun
    Shu, Yongqian
    Dong, Xiaorong
    Li, Lu
    Yoneshima, Yasuto
    Zhou, Chengzhi
    Li, Xiaoling
    Zhang, Yiping
    Huang, Dingzhi
    Zang, Aimin
    Zhang, Wei
    Wang, Xiuwen
    Zhang, Li
    Bai, Chong
    Fang, Jian
    Cao, Lejie
    Zhao, Yanqiu
    Yu, Yan
    Shi, Meiqi
    Zhong, Diansheng
    Li, Fugen
    Li, Meng
    Wu, Qiuxia
    Zhou, Jun
    Sun, Minghui
    Lu, Shun
    ECLINICALMEDICINE, 2023, 59
  • [46] Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.
    Lyu, Chao
    Wang, Rui
    Li, Shaolei
    Yan, Shi
    Wang, Yuzhao
    Chen, Jinfeng
    Wang, Liang
    Liu, Yinan
    Guo, Zhanlin
    Wang, Jia
    Pei, Yuquan
    Yu, Lei
    Wu, Nan
    Chen, Jun
    Liu, Yanheng
    Li, Shanqing
    Han, Bing
    Ding, Lieming
    Mao, Li
    Yang, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer
    Spicer, J.
    Provencio, M.
    Garrido Lopez, P.
    Bosch-Barrera, J.
    de Castro Carpeno, F. J.
    Felip, E.
    Trigo, J.
    Viteri, S.
    Coart, E.
    Schmidt, E.
    Christiansen, A. V.
    Zocca, M-B.
    Andersen, M. H.
    Ehrnrooth, E.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Predictive value of Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) in patients (pts) with EGFR exon 20 insertion (ex20ins)-positive metastatic non-small cell lung cancer (mNSCLC) receiving mobocertinib therapy
    Hofman, P.
    Su, Z.
    Tong, X.
    Bunn, V.
    Jin, S.
    Vincent, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1049 - S1049
  • [49] Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
    Xinghao Ai
    Zhengbo Song
    Hong Jian
    Zhen Zhou
    Zhiwei Chen
    Yongfeng Yu
    Ziming Li
    Shun Lu
    BMC Cancer, 21
  • [50] Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
    Ai, Xinghao
    Song, Zhengbo
    Jian, Hong
    Zhou, Zhen
    Chen, Zhiwei
    Yu, Yongfeng
    Li, Ziming
    Lu, Shun
    BMC CANCER, 2021, 21 (01)
12345